American Regent, Inc.

44 articles about American Regent, Inc.

• American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®

  8/26/2023

  American Regent, Inc., a Daiichi Sankyo Group company, announced results from the phase 3 HEART-FID trial of INJECTAFER® for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction.

• American Regent introduces FDA-approved Epinephrine Injection, USP

  3/30/2023

  American Regent announces the launch of sulfite-free Epinephrine Injection, USP.

• American Regent Launches a New Vial Presentation

  6/30/2022

  American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® Injection, USP in a 10 mL single-dose vial.

• American Regent announces the launch of Selenious Acid Injection, USP in a 12 mcg/2 mL single-dose vial.

  3/31/2022

  American Regent, Inc. is pleased to announce the launch of Selenious Acid Injection, USP in a new concentration and vial size.

• American Regent introduces FDA-approved Vasopressin Injection, USP

  2/3/2022

   American Regent announces the introduction and availability of FDA-approved Vasopressin Injection, USP.

• Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia

  12/16/2021

  Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.

• American Regent, Inc. Announces CEO Transition for 2021

  11/12/2020

  American Regent, Inc., a Daiichi Sankyo Group company, announced that Ken Keller, currently serving as the company's President and CEO, is transitioning to a new role as the Global Head of Oncology Business at Daiichi Sankyo, Inc. effective April 1, 2021.

• American Regent Inc Selects Sparta Systems' TrackWise Digital QMS to Seamlessly Connect Quality Across Manufacturing, Clinical and Supplier Network

  6/15/2020

  Today, Sparta Systems, Inc., the leading provider of quality management solutions for life sciences, announced that American Regent, Inc., a top-10 injectable manufacturer, has chosen TrackWise Digital® as its next generation cloud platform for manufacturing, clinical, and supplier management.

• American Regent Introduces Estradiol Valerate Injection, USP­; AO Rated and Therapeutically Equivalent to Delestrogen®1, 2

  6/3/2020

  American Regent announces the introduction and availability of Estradiol Valerate Injection, USP – AO Rated and therapeutically equivalent to Delestrogen®

• American Regent Introduces niCARdipine Hydrochloride Injection, USP­; AP Rated and Therapeutically Equivalent to Cardene® (1, 2)

  5/11/2020

  American Regent announced the introduction of the only FDA approved USP standard Nicardipine Hydrochloride Injection. Nicardipine Hydrochloride is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.

• American Regent to Hire More than 120 in New York and Ohio

  4/30/2020

  The company manufactures 99% of its medications in the United States, allowing it to reliably and quickly supply high-quality, life-saving treatments to those in need.

• American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility in France to Complement Its U.S. Manufacturing

  4/1/2020

  American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio , announced today that it will acquire Daiichi Sankyo Altkirch SARL, a Daiichi Sankyo company that has an Active Pharmaceutical Ingredient (API) pharmaceutical manufacturing plant in Altkirch, F

• American Regent, Inc. Moves Corporate Office to Melville, NY

  3/5/2020

  American Regent, Inc., a manufacturer and distributor of pharmaceuticals that addresses diverse medical and veterinary needs, announced that it has moved its corporate offices to Melville, New York.

• American Regent Introduces FDA Approved Zinc Sulfate Injection, USP

  1/28/2020

  American Regent, Inc. announced the introduction of FDA approved Zinc Sulfate Injection, USP.

• American Regent Announces the Re-Introduction of Aminocaproic Acid Injection, USP; AP Rated and Therapeutically Equivalent to Amicar®*(1)

  2/28/2019

  American Regent announced the re-introduction of Aminocaproic Acid Injection, USP, a therapeutically equivalent generic alternative to Amicar®.

• American Regent Re-introduces Droperidol Injection, USP; AP Rated and Therapeutically Equivalent to Inapsine®1*

  2/15/2019

  American Regent, Inc. announced the re-introduction of Droperidol Injection, USP.

• Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches

  8/31/2018

  Amneal Pharmaceuticals, Inc. today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena®

• American Regent, Inc. Announces Enrollment Of First Patient In Phase III Trial To Investigate Injectafer (Ferric Carboxymaltose) As Treatment For Heart Failure With Iron Deficiency

  4/24/2017

• American Regent, Inc.'s Injectafer® (Ferric Carboxymaltose Injection) Assigned J Code By Centers For Medicare & Medicaid Services

  12/15/2014

• American Regent, Inc. Announces Clinical Data Presentations At American Society of Hematology 2014

  12/8/2014